Your browser doesn't support javascript.
loading
Successful rapid desensitization for cetuximab-induced anaphylaxis
Allergy, Asthma & Respiratory Disease ; : 294-296, 2015.
Artículo en Coreano | WPRIM | ID: wpr-83768
ABSTRACT
Cetuximab, a chimeric mouse-human immunoglobulin, is an antiepidermal growth factor receptor monoclonal antibody. It has been approved by the U.S. Food and Drug Administration for the treatment of metastatic colorectal and head/neck cancer, but can cause fatal hypersensitivity reactions in some patients. A 66-year-old male with metastatic sigmoid cancer had cetuximab-induced anaphylaxis when the first dose of cetuximab was administered. Cetuximab was safely readministered for another 15 cycles based on the rapid desensitization protocol. We experienced a case of cetuximab-induced anaphylaxis on the first exposure which was successfully managed by rapid desensitization.
Asunto(s)

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Neoplasias del Colon Sigmoide / United States Food and Drug Administration / Inmunoglobulinas / Desensibilización Inmunológica / Cetuximab / Hipersensibilidad / Anafilaxia Tipo de estudio: Guía de Práctica Clínica Límite: Anciano / Humanos / Masculino Idioma: Coreano Revista: Allergy, Asthma & Respiratory Disease Año: 2015 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Neoplasias del Colon Sigmoide / United States Food and Drug Administration / Inmunoglobulinas / Desensibilización Inmunológica / Cetuximab / Hipersensibilidad / Anafilaxia Tipo de estudio: Guía de Práctica Clínica Límite: Anciano / Humanos / Masculino Idioma: Coreano Revista: Allergy, Asthma & Respiratory Disease Año: 2015 Tipo del documento: Artículo